Scholarlink

Despite the successful clinical development of PD-1/PD-L1 inhibitors in cancer treatment, only a small group of patients with breast cancer derive benefit from these agents. Therefore, additional mechanisms might be involved in the evasion of anticancer immunity leading to immunotherapy resistance in breast cancer. Different studies are addressing immune checkpoint inhibitors in combination with targeted treatment, mainly in metastatic disease. In this chapter, we will present the current clinical development of these combination strategies in breast cancer.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Clinical Development of Immune Checkpoint Inhibitors in Combination with Targeted Therapy in Breast Cancer

  • 章节

  • 发表日期：

    2024年

查看全文
  • Romualdo Barroso-Sousa,
  • Luiza N. Weis,
  • Sara M. Tolaney

摘要

Despite the successful clinical development of PD-1/PD-L1 inhibitors in cancer treatment, only a small group of patients with breast cancer derive benefit from these agents. Therefore, additional mechanisms might be involved in the evasion of anticancer immunity leading to immunotherapy resistance in breast cancer. Different studies are addressing immune checkpoint inhibitors in combination with targeted treatment, mainly in metastatic disease. In this chapter, we will present the current clinical development of these combination strategies in breast cancer.